Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Epizyme, Inc.EPZM · Entity 12703 | EVP & CFO | August 09, 2017 | August 10, 2017 |
| KYNTRA BIO, INC.KYNB · Entity 7431 | Director | October 01, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Epizyme, Inc.
Report date August 09, 2017 · Filed August 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Commons Stock, par value $0.0001SEC Table I · non-derivative | Direct | 45,446 |
Ending reported balance
After 2017-08-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-08-09 · Exercise / conversion · Acquired 1,682 · Balance 44,668 F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Row 2 · 2017-08-09 · Exercise / conversion · Acquired 778 · Balance 45,446 F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 30,274 |
Reported balance
After 2017-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-08-09 · Exercise / conversion · Disposed 1,682 · Balance 30,274 F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F2: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,992 |
Reported balance
After 2017-08-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-08-09 · Exercise / conversion · Disposed 778 · Balance 13,992 F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F3: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting.
F2: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.
F3: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.
KYNTRA BIO, INC.
Report date October 01, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2036-09-30 | Direct | 14,000 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 14,000 · Balance 14,000 F1: The shares subject to the option shall vest in twelve equal quarterly installments measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in twelve equal quarterly installments measured from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 6, 2026 22:06 UTC | KYNTRA BIO, INC. KYNB · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001632720-26-000004 · form4-10062026_101058.xml · derivative · entry 1 Singer Andrew E. · CIK 0001632720 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2036-09-30 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve equal quarterly installments measured from the date of grant. Read SEC document |
| August 09, 2017 Filed Aug 10, 2017 15:47 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-048398 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,992 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F3 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F3 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| August 09, 2017 Filed Aug 10, 2017 15:47 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-048398 · doc4.xml · derivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,274 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F2 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F2 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| August 09, 2017 Filed Aug 10, 2017 15:47 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommons Stock, par value $0.0001 | 778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-048398 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| August 09, 2017 Filed Aug 10, 2017 15:47 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommons Stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-048398 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 13:57 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044857 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,770 Underlying: Common Stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F3 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F3 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 13:57 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044857 · doc4.xml · derivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,956 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F2 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F2 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 13:57 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-044857 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 13:57 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-044857 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 15:47 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommons Stock, par value $0.0001 | 3,024 | $15.50 | $46,872.00 |
DisclosureSEC source: 0001209191-17-043174 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,529 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 15:47 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039124 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,547 Underlying: Common Stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F3 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F3 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 15:47 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039124 · doc4.xml · derivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,638 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F2 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F2 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 15:47 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommons Stock, par value $0.0001 | 777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-039124 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 15:47 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommons Stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-039124 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| May 09, 2017 Filed May 11, 2017 14:27 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031492 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,324 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F3 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F3 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| May 09, 2017 Filed May 11, 2017 14:27 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031492 · doc4.xml · derivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,320 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F2 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F2 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| May 09, 2017 Filed May 11, 2017 14:27 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-031492 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| May 09, 2017 Filed May 11, 2017 14:27 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-031492 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 13:34 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026541 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,102 Underlying: Common Stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F3 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 13:34 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026541 · doc4.xml · derivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,002 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F2 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 13:34 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-026541 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 13:34 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-026541 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 13:55 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon stock, par value $0.0001 | 2,013 | $17.09 | $34,394.12 |
DisclosureSEC source: 0001209191-17-024065 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,175 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.95 per share to $17.30 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 14:45 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-019799 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,879 Underlying: Common Stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F3 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 14:45 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-019799 · doc4.xml · derivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,684 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F2 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 14:45 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon stock, par value $0.0001 | 777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-019799 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 14:45 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-019799 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| February 09, 2017 Filed Feb 9, 2017 18:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009203 · doc4.xml · derivative · entry 5 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,656 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F4 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| February 09, 2017 Filed Feb 9, 2017 18:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,681 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009203 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,366 Underlying: Common Stock · 1,681 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F3 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| February 09, 2017 Filed Feb 9, 2017 18:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-009203 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| February 09, 2017 Filed Feb 9, 2017 18:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 1,681 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-009203 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 18:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 61,037 | $0.00 Strike: $12.45 | $0.00 |
DisclosureSEC source: 0001209191-17-009203 · doc4.xml · derivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,037 Underlying: Common Stock · 61,037 shares Expires 2027-02-07 F2 · derivative.exercise_date: This option was granted on February 8, 2017 pursuant to the Company's 2013 Stock Incentive Plan with respect to 61,037 shares of Common Stock, with 25% vesting on February 8, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 14:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-003085 · doc4.xml · derivative · entry 5 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,434 Underlying: Common Stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F5 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 14:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-003085 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,047 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F4 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 14:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon stock, par value $0.0001 | 1,013 | $12.04 | $12,194.39 |
DisclosureSEC source: 0001209191-17-003085 · doc4.xml · nonDerivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,270 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 per share to $12.30 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 14:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon stock, par value $0.0001 | 777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-003085 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 14:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-003085 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| December 09, 2016 Filed Dec 12, 2016 14:46 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-154663 · doc4.xml · derivative · entry 5 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,211 Underlying: Common Stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F5 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| December 09, 2016 Filed Dec 12, 2016 14:46 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-154663 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,729 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F4 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| December 09, 2016 Filed Dec 12, 2016 14:46 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,013 | $11.03 | $11,171.97 |
DisclosureSEC source: 0001209191-16-154663 · doc4.xml · nonDerivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,824 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.65 per share to $11.30 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2016 Filed Dec 12, 2016 14:46 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-154663 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| December 09, 2016 Filed Dec 12, 2016 14:46 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-154663 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:28 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-149514 · doc4.xml · derivative · entry 5 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,988 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F5 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:28 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-149514 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,411 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F4 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:28 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,013 | $10.40 | $10,535.20 |
DisclosureSEC source: 0001209191-16-149514 · doc4.xml · nonDerivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,378 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock. F3 · price: These shares were sold in multiple transactions at $10.40 per share. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:28 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-149514 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:28 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-149514 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 13:42 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-145682 · doc4.xml · derivative · entry 5 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,766 Underlying: Common Stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F5 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 13:42 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-145682 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,093 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F4 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 13:42 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,013 | $9.72 | $9,848.18 |
DisclosureSEC source: 0001209191-16-145682 · doc4.xml · nonDerivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,931 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.41 per share to $9.83 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.